Ledipasvir/sofosbuvir

Drug Profile

Ledipasvir/sofosbuvir

Alternative Names: GS 5885/PSI 7977; GS-5885/GS-7977; GS-5885/sofosbuvir; GS-7977/GS-5885; Harvoni; LDV/SOF; PSI 7977/GS 5885; Sofosbuvir/GS-5885; Sofosbuvir/ledipasvir

Latest Information Update: 23 Feb 2017

Price : $50

At a glance

  • Originator Gilead Sciences
  • Developer Gilead Sciences; The French National Agency for Research on AIDS and Viral Hepatitis
  • Class Antivirals; Azabicyclo compounds; Benzimidazoles; Carbamates; Fluorenes; Imidazoles; Phosphoric acid esters; Pyrimidine nucleotides; Small molecules; Spiro compounds
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 27 Jan 2017 Gilead Sciences plans the phase II LDV/SOF ESRD trial for Hepatitis C (NCT03036839)
  • 02 Dec 2016 The EMA’s Pharmacovigilance Risk Assessment Committee issues a warning about the risk of hepatitis B-reactivation with direct-acting antiviral drugs, including ledipasvir/sofosbuvir
  • 11 Nov 2016 Efficacy and adverse events data from a phase III trial in Hepatitis C presented at the 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top